Form 4: Neuronetics EVP, CFO and Treasurer Stephen Furlong Reports Acquisition of 157,500 Shares and 78,750 Performance Restricted Stock Units

Stephen Furlong, EVP, CFO and Treasurer of Neuronetics, Inc., reports the acquisition of 157,500 shares of common stock and 78,750 performance restricted stock units (PRSUs) on February 24, 2025.

Summary

• On February 24, 2025, Stephen Furlong, the EVP, CFO, and Treasurer of Neuronetics, Inc., acquired 157,500 shares of common stock.
• These shares were acquired at a price of $0.
• Furlong also acquired 78,750 performance restricted stock units (PRSUs) on the same date.
• Following these transactions, Furlong beneficially owns 611,920 shares of common stock.
• The PRSUs vest in three tranches on December 31, 2025, 2026, and 2027, subject to performance metrics and continuous service.
• Each RSU and PRSU represents a contingent right to receive one share of Neuronetics' common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by an executive is generally a good sign, indicating confidence in the company. However, it's a routine filing and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of shares and PRSUs by a key executive could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the performance restricted stock units is contingent upon the company's year-end cash balance being between 80% and 110% of the target for each fiscal year ending December 31, 2025, 2026 and 2027, and the Reporting Person's continuous service through those dates.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency regarding the alignment of management's interests with those of shareholders.

Comparison to Industry Standards

• Stock grants and performance-based equity compensation are standard practices in the biotechnology and medical device industries to incentivize executives.
• The vesting schedules and performance metrics are typical for such grants, aligning executive compensation with company performance and shareholder value.

Stakeholder Impact

• The stock and PRSU grants align management's interests with those of shareholders, potentially driving long-term value creation.
• Employees may view the executive's stock ownership as a positive sign of leadership commitment.

Key Dates